Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Melanoma Marker (MART-1 + Tyrosinase + gp100) Antibody (M2-7C10 + M2-9E3 + T311 + HMB45), Alexa Fluor™ 700, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP234681AF700
Description
Melanoma Marker (MART-1 + Tyrosinase + gp100) Monoclonal specifically detects Melanoma Marker (MART-1 + Tyrosinase + gp100) in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.Specifications
Melanoma Marker (MART-1 + Tyrosinase + gp100) | |
Monoclonal | |
Alexa Fluor 700 | |
MART1, MART-1, melan-A, MLANA | |
Recombinant hMART-1 protein (M2-7C10; M2-9E3); Recombinant tyrosinase protein (T311); Extract of pigmented melanoma metastases from lymph nodes (HMB45) | |
0.1 mL | |
Primary | |
This antibody cocktail recognizes three melanoma-specific proteins, which include MART-1, Tyrosinase and gp100. MART-1 is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Tyrosinase is one of the targets for cytotoxic T-cell recognition in melanoma patients. Function of gp100 is not known but it is reported to be a useful marker for melanocytes and melanomas. This cocktail of three markers is designed for extremely sensitive labeling of formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation. | |
Store at 4C in the dark. | |
IgG2b λ, IgG2a κ, IgG1 κ |
Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen) | |
M2-7C10 + M2-9E3 + T311 + HMB45 | |
Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen | |
Mouse | |
Protein A or G purified | |
RUO | |
2315 | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction